Cytokines as Biomarkers in Rheumatoid Arthritis
RA is a complex disease that develops as a series of events often referred to as disease continuum. RA would benefit from novel biomarker development for diagnosis where new biomarkers are still needed (even if progresses have been made with the inclusion of ACPA into the ACR/EULAR 2010 diagnostic c...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2014-01-01
|
| Series: | Mediators of Inflammation |
| Online Access: | http://dx.doi.org/10.1155/2014/545493 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850227642517684224 |
|---|---|
| author | Agata Burska Marjorie Boissinot Frederique Ponchel |
| author_facet | Agata Burska Marjorie Boissinot Frederique Ponchel |
| author_sort | Agata Burska |
| collection | DOAJ |
| description | RA is a complex disease that develops as a series of events often referred to as disease continuum. RA would benefit from novel biomarker development for diagnosis where new biomarkers are still needed (even if progresses have been made with the inclusion of ACPA into the ACR/EULAR 2010 diagnostic criteria) and for prognostic notably in at risk of evolution patients with autoantibody-positive arthralgia. Risk biomarkers for rapid evolution or cardiovascular complications are also highly desirable. Monitoring biomarkers would be useful in predicting relapse. Finally, predictive biomarkers for therapy outcome would allow tailoring therapy to the individual. Increasing numbers of cytokines have been involved in RA pathology. Many have the potential as biomarkers in RA especially as their clinical utility is already established in other diseases and could be easily transferable to rheumatology. We will review the current knowledge’s relation to cytokine used as biomarker in RA. However, given the complexity and heterogeneous nature of RA, it is unlikely that a single cytokine may provide sufficient discrimination; therefore multiple biomarker signatures may represent more realistic approach for the future of personalised medicine in RA. |
| format | Article |
| id | doaj-art-2001018b263749c4b16a455c470fb5d8 |
| institution | OA Journals |
| issn | 0962-9351 1466-1861 |
| language | English |
| publishDate | 2014-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Mediators of Inflammation |
| spelling | doaj-art-2001018b263749c4b16a455c470fb5d82025-08-20T02:04:45ZengWileyMediators of Inflammation0962-93511466-18612014-01-01201410.1155/2014/545493545493Cytokines as Biomarkers in Rheumatoid ArthritisAgata Burska0Marjorie Boissinot1Frederique Ponchel2Leeds Institute of Rheumatic and Musculoskeletal Medicine, The University of Leeds, Leeds, UKLeeds Institute of Cancer and Pathology Research, The University of Leeds, Leeds, UKLeeds Institute of Rheumatic and Musculoskeletal Medicine, The University of Leeds, Leeds, UKRA is a complex disease that develops as a series of events often referred to as disease continuum. RA would benefit from novel biomarker development for diagnosis where new biomarkers are still needed (even if progresses have been made with the inclusion of ACPA into the ACR/EULAR 2010 diagnostic criteria) and for prognostic notably in at risk of evolution patients with autoantibody-positive arthralgia. Risk biomarkers for rapid evolution or cardiovascular complications are also highly desirable. Monitoring biomarkers would be useful in predicting relapse. Finally, predictive biomarkers for therapy outcome would allow tailoring therapy to the individual. Increasing numbers of cytokines have been involved in RA pathology. Many have the potential as biomarkers in RA especially as their clinical utility is already established in other diseases and could be easily transferable to rheumatology. We will review the current knowledge’s relation to cytokine used as biomarker in RA. However, given the complexity and heterogeneous nature of RA, it is unlikely that a single cytokine may provide sufficient discrimination; therefore multiple biomarker signatures may represent more realistic approach for the future of personalised medicine in RA.http://dx.doi.org/10.1155/2014/545493 |
| spellingShingle | Agata Burska Marjorie Boissinot Frederique Ponchel Cytokines as Biomarkers in Rheumatoid Arthritis Mediators of Inflammation |
| title | Cytokines as Biomarkers in Rheumatoid Arthritis |
| title_full | Cytokines as Biomarkers in Rheumatoid Arthritis |
| title_fullStr | Cytokines as Biomarkers in Rheumatoid Arthritis |
| title_full_unstemmed | Cytokines as Biomarkers in Rheumatoid Arthritis |
| title_short | Cytokines as Biomarkers in Rheumatoid Arthritis |
| title_sort | cytokines as biomarkers in rheumatoid arthritis |
| url | http://dx.doi.org/10.1155/2014/545493 |
| work_keys_str_mv | AT agataburska cytokinesasbiomarkersinrheumatoidarthritis AT marjorieboissinot cytokinesasbiomarkersinrheumatoidarthritis AT frederiqueponchel cytokinesasbiomarkersinrheumatoidarthritis |